MDMA-Assisted Therapy Application Moves Forward
The FDA is reviewing a new application that could provide a potential treatment option for millions of Americans with PTSD.
Updated on Oct. 23, 2026 in Substance Abuse
Live Poll
Should the FDA approve MDMA-assisted therapy for treating PTSD patients?
Resilient Pharmaceuticals, formerly Lykos Therapeutics, resubmitted its application for MDMA-assisted therapy in August 2026. The therapy, aimed at helping the 13 million Americans with PTSD, could potentially receive FDA approval as early as January 2027.
Why it matters
The FDA previously rejected this application in 2024, citing concerns about trial data reliability. This resubmission seeks to address these gaps using existing research from other groups, including the Department of Veterans Affairs, rather than starting a new Phase 3 trial.
The application relies on synthesized research data, including studies from the Department of Veterans Affairs, to support efficacy. Whether this information sufficiently addresses prior concerns about trial data integrity is currently under investigation by federal regulators.
The players
Resilient Pharmaceuticals
A developer of mental health treatments formerly known as Lykos Therapeutics.
Department of Veterans Affairs
A federal agency that provides care to military veterans and conducts clinical research on PTSD treatments.
Eli Lilly
A global pharmaceutical company that recently expanded into the psychedelic-based mental health sector.
President of the United States
The head of the executive branch who issued an order to accelerate research into psychedelic medicine.
The details
MDMA-assisted therapy is designed to work in conjunction with psychological support to help patients process trauma. By utilizing a drug to facilitate therapeutic sessions, researchers aim to improve recovery rates for those struggling with PTSD. Resilient Pharmaceuticals is moving forward without the additional Phase 3 trial initially requested by the FDA.
Timeline
August 2024: The FDA rejected the initial MDMA-assisted therapy application from Lykos Therapeutics.
April 2026: President Trump signed an executive order to increase federal psychedelic research.
July 2026: Eli Lilly acquired AtaiBeckley for $2.8 billion.
August 2026: Resilient Pharmaceuticals resubmitted its application to the FDA.
December 2026: MAPS is scheduled to host its first US training for this therapy.
Health Landscape
The push for MDMA-assisted therapy aligns with the April 2026 Executive Order on psychedelic research, which aims to accelerate federal approval pathways. This development represents a broader effort to integrate alternative substances into standard mental health care protocols.
Patients living with PTSD should discuss the current status of emerging therapies with a mental health professional to understand available care options. Because these treatments are not yet FDA-approved, it is critical to focus on standard, evidence-based care while monitoring regulatory updates.
The takeaway
While research into MDMA-assisted therapy suggests potential benefits for trauma recovery, formal approval is still pending federal review. Patients and families should track major regulatory announcements in early 2027 and maintain consistent contact with their primary care providers for ongoing mental health needs.
What happens next
The FDA could render a decision on the application as early as January 2027, with final approval potentially coming by the end of the first quarter of 2027.
Further reading
For more information on the evolving landscape of treatments, visit our Substance Abuse section.
Live Poll
Should the FDA approve MDMA-assisted therapy for treating PTSD patients?
